Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladostigil in mild to moderate Alzheimer's disease
NCT01354691Phase 2Completed
- Sponsor
- Avraham Pharmaceuticals Ltd.
- Start
- Feb 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Ladostigil with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 26 weeks. Started Feb 2011; status: completed.
02
Drugs
ladostigil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01354691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01354691.